Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
|Articles|April 12, 2017
Uncovering Mechanisms Associated With ADT Resistance in Prostate Cancer
Author(s)David Goodrich, PhD
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Advertisement
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Dr. Goodrich
Advertisement
Related to this article
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
2
FDA OKs Pirtobrutinib in Frontline CLL/SLL
3
Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5